Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Two-Arm Open-Label Study of Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression

NCT03724968 is registered in ClinicalTrials.gov with Elizabeth Davis as lead sponsor.

NCT NCT03724968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03724968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Two-Arm Open-Label Study of Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
Lead sponsor
Elizabeth Davis
Phase
Phase 2
Overall status
Terminated
Start date
January 17, 2019
Completion date
May 28, 2020
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma, metastatic melanoma, metastatic melanoma stratified by mhc-ii expression